Clinical Trials Logo

Sepsis clinical trials

View clinical trials related to Sepsis.

Filter by:

NCT ID: NCT05413343 Recruiting - Severe Sepsis Clinical Trials

Clinical Study on Monitoring the Plasma Concentration of Ceftazidime-Avibactam in Critically Ill Patients

Start date: January 1, 2022
Phase:
Study type: Observational [Patient Registry]

A observational study is conducting at the First Affiliated Hospital of the Medical College of Zhejiang University from January 1, 2022 to January 1, 2024. Patients with severe sepsis and treatment with Ceftazidime-Avibactam will be enrolled. Blood samples at different timepoints: 0 hour, 2 hours, 4 hours, 6 hours, and 8 hours after the first time and the steady state concentration(more than 4 times drug administration) of drug administration will be collected to detect plasma drug concentrations of ceftazidime avibactam.

NCT ID: NCT05410665 Recruiting - Sepsis Clinical Trials

The Roles of IL-9/E-cadherin and Ferroptosis in Intestinal Mucosal Barrier Injury in Sepsis

Start date: May 31, 2022
Phase:
Study type: Observational

The investigators aim to evaluate the roles of IL-9/E-cadheirin and ferroptosis in the intestinal mucosal barrier injury of sepsis. The results of this study would lay the foundation for revealing the mechanisms of EEN improving immune imbalance of sepsis and provide a new idea to the early treatment of sepsis.

NCT ID: NCT05402553 Recruiting - Sepsis Clinical Trials

The Efficacy of Adjunctive Use of Ondansetron in Patients With Sepsis and Septic Shock

Start date: April 24, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Sepsis is a systemic inflammatory response that has deleterious effects and considered the leading cause of death in critically ill patients 1 . One of the hallmarks of severe sepsis is the progressive, injurious inflammatory response to infection, mediated by the excessive release of inflammatory mediators and consequently, associated with multiple organs damage 2 . Various studies have demonstrated that adverse outcomes in sepsis patients are closely related to the development of myocardial dysfunction 3 . The mortality of sepsis combined with cardiac functional insufficiency has increased significantly to 70%-90% 4 . Therefore, targeting cardiac insufficiency and heart injury may represent a novel treatment strategy. Several reports documented critical involvement of serotonin 5-hydroxytryptamine in the pathogenesis of sepsis. The aim of the current study is to evaluate the efficacy of ondansetron adjuvant use in patients with sepsis and septic shock.

NCT ID: NCT05399225 Recruiting - Clinical trials for Platelets to Lymphocytes Ratio Sepsis

Platelets to Lymphocytes Ratio in Sepsis

Start date: September 2022
Phase:
Study type: Observational [Patient Registry]

The aim of this study is to compare effectiveness of platelets to lymphocytes ratio (PLR) with procalcitonin as a predictor of sepsis outcome.

NCT ID: NCT05386199 Recruiting - Sepsis Clinical Trials

The Role of Serotonin in Intensive Care Patients

SERO-22
Start date: May 25, 2022
Phase:
Study type: Observational

Sepsis, cardiac arrest and multiple trauma are potentially life-threatening conditions and common reasons for intensive care unit (ICU) admission. The aim of this study is to investigate the role of the signaling substance serotonin in blood in these conditions.

NCT ID: NCT05383963 Recruiting - Sepsis Clinical Trials

Evaluation of Parameters Collected From Routine Data for the Diagnosis of Sepsis and Septic Shock and Their Influence on Time to Diagnosis and Patient Outcome

Start date: July 15, 2022
Phase:
Study type: Observational

Retrospective observational study to develop a Machine Learning Algorithm to evaluate parameters collected from routine data for the diagnosis of sepsis and septic shock and their influence on time to diagnosis and patient outcome.

NCT ID: NCT05376566 Recruiting - Clinical trials for Central Line-associated Bloodstream Infection (CLABSI)

Hydrochloric Acid Lock Therapy for Central Line-associated Bloodstream Infections

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

Aim: This study will test whether treatment of central line-associated bloodstream infections (CLABSI) with hydrochloric acid lock therapy (HALT) can significantly reduce the risk of treatment failure (comprising failure to clear initial infection, relapse of infection, or reinfection) in patients treated for cancer or hematologic diseases. Study design: A multicentre, double-blinded, randomized controlled trial. Patient population: Patients (0-100 y) with cancer or a hematologic disorder and a CLABSI treated at Copenhagen University Hospital, Aarhus University Hospital, or Odense University Hospital, Denmark. Randomization: Patients are equally assigned (1:1) to receive either HALT or placebo (normal saline). In addition to the study intervention, patients in both arms will receive standard systemic antibiotic therapy. Sample size: A target population of 250 patients

NCT ID: NCT05357339 Recruiting - Sepsis Clinical Trials

Microcirculation Properties of Albumin for Fluid Resuscitation in Septic Shock

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

The sublingual microcirculation is impaired in sepsis and septic shock. Sidestream dark field imaging technology has been developed into a clinical tool to help the clinician assess the microcirculation at the bedside. The ideal resuscitation fluid has not been identified. The investigators aim to use this new bedside technology to establish the microcirculation properties of two popular resuscitation fluids.

NCT ID: NCT05357170 Recruiting - Clinical trials for Sepsis, Trauma Injury

Gut Microbiome Dysfunction in Sepsis and Trauma Survivors

Start date: June 21, 2022
Phase:
Study type: Observational

Gastrointestinal microbiome dysfunction has been demonstrated to be a culprit of various systemic dysfunctions in peripheries such as cardiovascular, nervous, endocrine and musculoskeletal systems. The topic of microbiome dysfunction after sepsis and trauma injury is understudied but may be responsible for persistent systemic inflammation clinically observed in sepsis and trauma survivors. Therefore, the objective of this project is to investigate the gut microbiome after acute phase of sepsis or severe trauma injury and compare it with 108 age-matched healthy population controls

NCT ID: NCT05349370 Recruiting - Sepsis Clinical Trials

Lactate Kinetics in Septic Shock

LKISS
Start date: December 28, 2022
Phase: N/A
Study type: Interventional

Lactate kinetics will be studied in hospitalized septic patients using a bolus injection of stable isotopically labeled lactate.